US 9492442

I'll search for authoritative information on this specific patent number and any current litigation activity.

Let me dig deeper on the claim text, litigation, and any 2026 appellate activity involving this specific patent.

Let me verify the granted claim text and check for any 2026 Federal Circuit activity.

US 9,492,442 B2 — Analyst Summary

Caveat up front: The full claim set did not appear in the authoritative Google Patents text I retrieved (the description was truncated mid-sentence at "therapeutically superio…"). Claim language below comes from a secondary aggregator (drugpatentwatch.com) and should be verified against USPTO Patent Center/PTActs before being relied on. I flag one specific inconsistency in §4 below. I also found no Federal Circuit 2026 docket involving this patent (§6).

1. Bibliographic data (per Google Patents, fetched 2026-09-28)

Orange Book linkage (drugpatentwatch, updated 2026-06-09): listed against ONIVYDE (irinotecan hydrochloride, liposomal; IV), NDA 207793-001, approved 2015-10-22, with use code "TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN." Reported as having ~50 family members across 21 countries (e.g., AU 2013202947/2013274287/2018201942; CA 2875824; BR 112014031088; CN 104717961/110051631).

2. Abstract (verbatim, Google Patents)

"Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin."

3. What the specification discloses (context for the claims)

• MM-398 / PEP02: irinotecan encapsulated as irinotecan sucrose octasulfate in ~80–140 nm unilamellar liposomes of phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (~1 PEG per 200 phospholipids); cross-referenced to U.S. Pat. No. 8,147,867. Dosing is preceded by dexamethasone ± a 5-HT3 antagonist; diluted in 500 mL of 5% dextrose (D5W); infused over 90 minutes.
• Two dosing regimens are described: (i) q3w monotherapy at 120 mg/m² (day 1), and (ii) q2w combination with 5-FU 2400 mg/m² (46-h infusion) and leucovorin 200 mg/m² (l-form) or 400 mg/m² (l+d racemic), with MM-398 given first.
• UGT1A1*28 pharmacogenetics: homozygotes (7/7) receive a reduced first-cycle dose — 80 mg/m² in the q3w regimen, 60 mg/m² in the q2w regimen — then escalate (by 20 mg/m² increments up to 120 mg/m² in q3w; to 80 mg/m² in q2w). Also discusses UGT1A1*6 (Asian populations) and DPYD.
• Phase 3 (NAPOLI-1) design (FIG. 7): Arm A = MM-398 120 mg/m² q3w; Arm B = 5-FU/LV; Arm C = MM-398 80 mg/m² q2w + 5-FU/LV; primary endpoint overall survival; secondary endpoints PFS, ORR, TTF, CA 19-9 response, QoL (EORTC-QLQ-C30), PK; Bonferroni-Holm testing; enrollment limited to metastatic pancreatic cancer progressing on gemcitabine.
• Preclinical data: MM-398 anti-tumor activity in orthotopic L3.6pl pancreatic model (FIG. 1), SN-38 tumor accumulation (FIG. 2), reduced CAIX/hypoxia and increased microvessel density in HT29 xenografts (FIG. 3), improved Hoechst 33342 perfusion (FIG. 4) — the basis for a disclosed "increasing tumor vascularity" aspect.
• Definitions: "co-administration/combination therapy" covers simultaneous or sequential administration of ≥2 agents where the first agent is still present when the second is given; "therapeutic synergy" per Corbett et al. (1982).

4. Independent claims — plain-language overview

Based on the drugpatentwatch claim listing, the patent appears to have two independent claims (1 and 10), with claims 2–9 depending from 1 and claim 11 depending from 10.

Claim 1 — A method of treating exocrine pancreatic cancer in a patient by administering a liposomal irinotecan composition together with therapeutically effective amounts of leucovorin and 5‑fluorouracil, where the liposomal irinotecan composition is structurally defined as comprising phosphatidylcholine, cholesterol and a PEG-derivatized phosphatidylethanolamine, with liposomes ~80–140 nm in diameter. (In the truncated snippet, the opening dosing/patient-population limitation of claim 1 is not captured.)

Claim 10 — A method of treating exocrine pancreatic cancer in a patient previously treated with gemcitabine, comprising intravenously administering an antineoplastic therapy "consisting of" (closed transition): (a) a 60–80 mg/m² dose of liposomal irinotecan, the formulation having been obtained by diluting a 5 mg/mL liposomal irinotecan composition into 500 mL of injectable liquid; plus (b) 200 mg/m² l-form leucovorin and 2,400 mg/m² 5‑FU; where the liposomes encapsulate irinotecan sucrose octasulfate and contain PC/cholesterol/PEG-PE at ~80–140 nm; and where the three agents are administered sequentially beginning on day 1 of a 2‑week cycle.

Representative dependent claims: 2 (≈1 PEG per 200 phospholipids); 3 (unilamellar vesicles encapsulating irinotecan sucrose octasulfate); 4 (disease progressed on gemcitabine); 5 (LV 200 mg/m² l-form or 400 mg/m² racemic; 5-FU 2,400 mg/m²); 6 (sequential dosing on day 1 of a 2-week cycle, all three simultaneously present in blood); 7 (liposomal irinotecan before 5-FU); 8 (prior gemcitabine treatment + specific lipid/PEG limitations); 9 (storage of diluted formulation at ~2–8 °C for ≤24 h); and 11 (same storage limitation appended to claim 10).

⚠️ Inconsistency to resolve: The specification's own summary section emphasizes two other claim families — a q3w 120 mg/m² monotherapy (with 80 mg/m² first cycle for UGT1A128 homozygotes) and a q2w 80 mg/m² + 5‑FU/LV regimen with 60 mg/m² first-cycle reduction. Those UGT1A128-specific limitations do not appear in the claim text I recovered from drugpatentwatch. Possible explanations: (a) the aggregator is displaying amended/reexamined claims, (b) it is displaying claims of a sibling family member (e.g., US 9,717,724 / 10,980,795 / 11,369,597 / 11,344,552), or (c) simple data mismatch. I cannot confirm the operative claim set from the sources fetched and recommend checking the USPTO Patent Center "Claims" tab / any reexamination certificate for the '442 patent.

5. USPTO-side proceedings

• Ex parte / IPR directly on the '442 patent: I found no IPR petition naming US 9,492,442. The PTActs petitions surfaced in my search target U.S. Pat. No. 11,344,552 (the NALIRIFOX/liposomal-irinotecan + oxaliplatin patent, effective filing date 2015-08-21), where CSPC Pharmaceutical Group/CSPC Ouyi/Conjupro filed an IPR (petition of 2025-01-17) relying on Conroy/FOLFIRINOX and "Bayever" as lead references, and Apotex filed a follow-on "silent understudy" petition; Ipsen requested discretionary denial under the March 26, 2025 PTAB workload memorandum. Note that the "Bayever" reference (Ex. 1006) relied on in those proceedings — cited for Arm C at pages 32–34, second-line gemcitabine-progressed patients at p. 26, and dosing language at pp. 12–13 — matches the disclosure of this '442 specification.
• Patent-term/priority note: the '442 family's Orange Book expiration is asserted at 2033-06-12; the litigated NALIRIFOX patent ('552) has been argued to have an effective filing date of 2015-08-21, i.e., these are separate priority chains.

6. Litigation / CAFC 2026 dockets

• No Federal Circuit appeal involving US 9,492,442 was found. Searches of 2026 CAFC activity returned only unrelated cases (Ironburg v. Valve, 2024-2088 (Fed. Cir. June 18, 2026); Teva v. Lilly, 2024-1094 (Apr. 16, 2026); International Medical Devices v. Cornell, 2025-1580/1605 (Apr. 17, 2026); Sanofi Appeal 2026-000193). Nothing in the retrieved results names 9,492,442 as an appellate docket patent. Treat this as "no evidence found," not as proof of absence.
• Active district court litigation (Hatch‑Waxman, ANDA/505(b)(2)): Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc.; CSPC Ouyi Pharmaceutical Co., Ltd.; CSPC Pharmaceutical Group Ltd., D.N.J. — reported both as 3:24‑cv‑04991 (Google Patents family-litigation link) and 1:24‑cv‑04991 (RMB)(MJS) (CourtListener/PACER), complaint filed April 15, 2024. The defendants' notice letter under 21 U.S.C. §355(b)(2)(A)(iv) (NDA No. 218923, "Conjupro/Conjuro" irinotecan liposome injection) challenged, inter alia, U.S. Pat. Nos. 8,329,213; 9,339,497; 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; 11,369,597; 8,147,867; 10,456,360; and 10,993,914. So the '442 patent is one of the patents-in-suit.
• Related consolidated actions: 24‑cv‑08723 (asserting US 12,059,497, filed Aug. 23, 2024; consolidated Oct. 18, 2024 into 24‑4991) and 25‑cv‑13647 (asserting a '691 patent issued ~July 22, 2025; consolidated Aug. 21, 2025). Defendants also filed counterclaims challenging Orange Book listing of later family patents.

7. Uncertainty statement

• High confidence: bibliographic data, title, abstract, inventors, assignees, dates, and the specification content (Google Patents primary text + the PTAB record's characterization of "Bayever").
• Moderate confidence: the claim-1/claim-10 independent-claim summary, which rests on a secondary aggregator and on a snippet that truncated claim 1's preamble; the exact number and wording of all claims (especially whether UGT1A1*28 and 3-week/120 mg/m² limitations survive in the issued claims) is unverified.
• Not established: any 2026 Federal Circuit docket for this patent; any IPR or reexamination specifically of the '442 patent; and whether any of the secondary sources are conflating the '442 patent with its continuation/divisional siblings.

I'll research litigation involving US 9,492,442 across patent litigation databases.

Let me dig into the specific District Court case referenced and related Hatch-Waxman litigation.

I have a strong lead. Let me verify the case details and check for any other litigation involving the '442 patent specifically.

Litigation involving U.S. Patent No. 9,492,442

Short answer: I found one patent litigation in which U.S. 9,492,442 ("the '442 patent") has been asserted. It is a Hatch‑Waxman / ANDA patent‑infringement action in the District of New Jersey. I found no CAFC appeal, no ITC action, and no other district‑court case asserting this specific patent.

Case 1 — Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.

The '442 patent's role in the case:

• The '442 patent is Exhibit E to the Complaint (issued November 15, 2016; titled "Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan").
• It is one of eight patents‑in‑suit in the original April 15, 2024 complaint, together with U.S. Patents 8,329,213; 9,339,497; 9,364,473; 9,452,162; 9,717,724; 10,980,795; and 11,369,597.
• The action arises from Conjupro's submission of NDA No. 218923 for a generic/505(b)(2) irinotecan liposome injection (a proposed version of Ipsen's Onivyde®) with a Paragraph IV certification that, inter alia, the '442 patent is invalid, unenforceable, and/or not infringed. Conjupro's notice letter was received by Ipsen at the latest by March 7, 2024; Ipsen sued within the 45‑day statutory window.
• Counterclaims: Conjupro/CSPC filed counterclaims seeking declaratory judgments of non‑infringement and invalidity of the '442 patent (Count directed to the '442 patent among the family of counterclaim patents), and the Defendants formally denied that the '442 patent "was duly and legally issued" and denied infringement. A jury trial was demanded on all triable issues.

Related/consolidated cases involving the same parties (NOT asserting the '442 patent):

• 1:24-cv-08723 (filed Aug. 23, 2024) — asserted U.S. 12,059,497; consolidated into 24‑4991 on Oct. 18, 2024.
• 1:25-cv-13647 (filed July 22, 2025) — asserted U.S. 12,364,691; consolidated into 24‑4991 on Aug. 21, 2025.

IPR note: The inter partes review petitions involving these parties (PTO IPR Nos. 25‑00505 and 25‑01531, instituted and joined for trial) concern U.S. 11,344,552 (the '552 patent) — not the '442 patent. I found no IPR/PGR challenging the '442 patent.

Caveats and confidence

• Confidence: high that the Ipsen v. Conjupro case (1:24-cv-04991) is the litigation asserting the '442 patent. This is corroborated by the Google Patents litigation link on the patent page itself (listed as New Jersey District Court case 3:24-cv-04991); Docketbird/Dockets.Justia party records; DrugPatentWatch; and the Paragraph IV case listing on paragraphfour.com (which expressly lists 9,492,442 among the "Litigated Patents").
• Confidence: moderate on current procedural posture. The most recent third‑party status summaries describe the consolidated case as being in discovery, but docket databases were last refreshed at different dates and PACER would be the authoritative source for the live status. I did not find a trial date, final judgment, or settlement term.
• Scope of search: Based on the sources retrieved, I did not find any other lawsuit asserting the '442 patent, any appeal at the CAFC, or any ITC proceeding involving it. Other ANDA filers may exist against Onivyde, but I could not confirm any other case naming the '442 patent specifically. This is not a guarantee that no such proceeding exists; treat it as "none found."

Recommended verification

For an authoritative, current record, pull the PACER docket for D.N.J. 1:24-cv-04991 (and the administratively terminated 1:24-cv-08723), and check the USPTO PTAB for any petition against U.S. 9,492,442, plus CAFC docket for any appeal.

I'll verify the PTAB posture for US 9,492,442 with targeted searches, since the ODP block reports no indexed AIA trials.

Let me dig deeper to confirm whether any AIA trial targets the '442 patent specifically (the results so far conflate other "*442" patents).

Proceedings overview

Total AIA trial proceedings on US 9,492,442: 0. The USPTO ODP structured block is the canonical list and returns nothing; my independent web checks (PTAB petition document servers, DrugPatentWatch PTAB tables for Onivyde/irinotecan, and Paragraph IV docket trackers) also surfaced no IPR, PGR, or CBM naming the '442 patent. What exists is (a) an active Hatch‑Waxman Paragraph IV litigation in D.N.J. in which the '442 patent is one of the asserted Orange Book patents, and (b) two AIA trials against a different patent in the same family, US 11,344,552 (IPR2025‑00505 and IPR2025‑01531). Bottom line for a defendant today: the '442 patent has never been administratively tested — its claims are all UNTESTED at the PTAB, not canceled and not sustained — and it remains a live, asserted Orange Book patent with an anticipated expiry of 2033‑06‑12. Do not treat the absence of IPRs as a clean bill of health, and do not assume a ’442-based demand letter is frivolous; but also recognize that no petitioner has yet taken the shot.

No proceedings on US 9,492,442

There are no entries to report under the requested per-proceeding template. I am not able to give you a petitioner, filing date, panel, institution decision, FWD, settlement, or appeal for the '442 patent, because none exists on the public record I could verify. Any claim-level FWD outcome for the '442 patent would be fabricated, and I will not state one.

For completeness: several search hits referencing a “’442 patent” IPR concern different patents — U.S. 8,929,442 (Realtime Adaptive Streaming/ARRIS, IPR2019‑01585/01586) and U.S. 10,484,442 (Meta v. TIR Technologies, IPR2026‑00347). Those are unrelated to liposomal irinotecan and are not proceedings on US 9,492,442.

IPR2025-00505 — CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., and Conjupro Biotherapeutics, Inc. v. Ipsen Biopharm Ltd. (different patent — US 11,344,552, not 9,492,442)

Included as the single most relevant strategic signal, clearly flagged as not a proceeding on the '442 patent.

• Type: Inter Partes Review (35 U.S.C. § 102/§ 103, patents/printed publications)
• Filed: 2025‑01‑17
• Status: Instituted; trial ongoing as of the last confirmation available
• Judge panel: Zhenyu Yang, Tawen Chang, and Timothy G. Majors, Administrative Patent Judges (panel composition as reflected in the related joinder decision, Paper in IPR2025‑01531)
• Petition grounds: Claims 1–15 of the '552 patent. Ground 1 — claims 1, 3–6, 8–14 obvious over FOLFIRINOX art (Conroy; Conroy Protocol; Conroy Appendix; Mahaseth) in view of Bayever (WO 2013/188586), Saif, Ko, Cantore. Ground 2 — claims 2, 7, 15 obvious over the Ground 1 art in further view of Masi and Ginocchi (administration-sequence limitations, e.g., oxaliplatin 2 hours after liposomal irinotecan). Core theory: substituting liposomal irinotecan for free irinotecan in the first‑line FOLFIRINOX regimen, with oxaliplatin at the 60 mg/m² claimed dose, was an obvious, predictability‑driven variation.
• Institution decision: Instituted 2025‑08‑14 (per DrugPatentWatch PTAB table). I have not independently reviewed the Board's institution reasoning text, so I am not quoting it.
• Final Written Decision: Not confirmed in my sources. Institution was 2025‑08‑14, so the statutory § 316(a)(11) one‑year deadline ran to approximately 2026‑08‑14, and oral argument was reportedly calendared for 2026‑05‑19. I could not verify a publicly posted FWD or its claim‑level outcome; I will not guess.
• Settlement / termination: None reported.
• Appeal: None reported.
• Defensive value: This is proof that the same NDA/Paragraph IV challenger is willing to litigate Onivyde patents at the PTAB — and chose the '552 patent, not the '442. That choice is itself a data point about how the challenger has prioritized the portfolio. Source: https://ai-lab.exparte.com/case/ptab/IPR2025-00505/doc/1006

IPR2025-01531 — Apotex Inc. v. Ipsen Biopharm Ltd. (different patent — US 11,344,552; terminated by joinder)

• Type: Inter Partes Review
• Filed: 2025‑09‑12
• Status: Terminated — petitioner joined as a silent understudy in IPR2025‑00505 (granted under 35 U.S.C. § 315(c); IPR2025‑01531 terminated under 37 C.F.R. §§ 42.72, all filings moved to IPR2025‑00505)
• Judge panel: Zhenyu Yang, Tawen Chang, and Timothy G. Majors
• Petition grounds: Claims 1–15 of the '552 patent; Apotex represented that its petition and supporting declaration were “substantially identical” to those in IPR2025‑00505.
• Institution decision: Institution granted (via the IPR2025‑00505 institution); the joinder decision notes “The Director granted institution of inter partes review.”
• Final Written Decision: N/A as a separate proceeding (silent understudy).
• Defensive value: Shows a second, independent ANDA filer (Apotex) joining the challenge — the classic pattern of a generic cohort coordinating on the weakest patent in a family, and leaving the '442 patent alone. Source: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1558479](/patent/1558479)/download-documents

The real '442 exposure is the district court case, not the PTAB

• Case: Ipsen Biopharmaceuticals, Inc. and Ipsen Biopharm Ltd. v. Conjupro Biotherapeutics, Inc. and CSPC entities, D.N.J. 1:24‑cv‑04991 (Judge Renee Marie Bumb; referred to Magistrate Matthew J. Skahill), filed 2024‑04‑15.
• Consolidated with: 1:24‑cv‑08723 (filed 2024‑08‑23, over US 12,059,497) and 1:25‑cv‑13647 (filed 2025‑07‑22, over US 12,364,691).
• '442 status in the case: Asserted as Count V; Ipsen pleads infringement under 35 U.S.C. § 271(e)(2)(A) and seeks a § 271(e)(4)(A) order setting the Conjupro NDA approval date no earlier than patent expiry. Defendants answered with non‑infringement and invalidity under 35 U.S.C. §§ 101, 102, 103, and/or 112 (Ninth and Tenth Defenses), and filed counterclaims seeking declarations that the '442 and sibling patents are invalid/unenforceable/not infringed.
• Orange Book: '442 is listed for NDA 207793 (ONIVYDE), use code U‑1917 (“treatment of exocrine pancreatic cancer that has progressed on gemcitabine‑based therapy, in combination with 5‑fluorouracil and leucovorin”), anticipated expiration 2033‑06‑12.
• Sources: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=IPSEN+BIOPHARMACEUTICALS%2C+INC.+v.+CONJUPRO+BIOTHERAPEUTICS%2C+INC.%7C1%3A24-cv-04991 ; https://paragraphfour.com/wp-content/uploads/2024/04/njdc24cv8723A.pdf ; https://www.drugpatentwatch.com/p/patent/9492442

Strategic summary

Claim status on the '442 patent: everything is UNTESTED. No claim of US 9,492,442 has been canceled, confirmed, or amended by the PTAB, because no AIA trial has ever been filed against it. There is no surviving‑claims list to hand you because there is no narrowing. The claims you must contend with are the original, as‑issued claims from the 2015‑09‑11 application (US 14/851,111), granted 2016‑11‑15, in the Bayever et al./Ipsen family that includes 9,339,497, 9,364,473, 9,452,162, 9,717,724, 10,980,795, 11,369,597 and 11,344,552. The asserted use is second‑line metastatic pancreatic adenocarcinoma post‑gemcitabine in combination with 5‑FU/leucovorin (Orange Book U‑1917).

Estoppel landscape. Because there is no IPR, 35 U.S.C. § 315(e)(2) estoppel does not exist against anyone on the '442 patent. Conjupro/CSPC (and their privies) litigated the IPR on the '552 patent only, so any estoppel they incurred runs to the '552 patent's challenged grounds (claims 1–15, the Conow/Mahaseth/Bayever/Saif/Ko/Cantore and Masi/Ginocchi combinations) — not to the '442 patent. Practically, this cuts both ways: (i) no prior‑art ground is foreclosed to a new defendant challenging the '442 at the PTAB, but (ii) the time bar matters — Conjupro/CSPC were served with the complaint asserting the '442 on or about 2024‑04‑15, so their § 315(b) one‑year window to IPR the '442 expired around 2025‑04‑15 and they are now time‑barred as to that patent (subject to joinder/§ 315(b) exceptions). For anyone not yet served, the full § 102/§ 103 arsenal remains available — and note the '442's priority date of 2012‑06‑13 with a 2013‑06‑12 PCT filing, which puts a lot of FOLFIRINOX/MM‑398 art (e.g., Conroy 2011, and Bayever WO 2013/188586 as a § 102(e)/§ 103 reference only if it predates) in play.

Pattern signals. No repeat petitioner on the '442 because there are no petitions at all. The pattern across the family is consistent and instructive: the same challenger (CSPC/Conjupro) filed one IPR — on the newest, narrowest method patent ('552, first‑line FOLFIRINOX‑type regimen) — and Apotex joined as a silent understudy; both are Hatch‑Waxman defendants who took the cheaper administrative path only where the claims were easy to attack on printed‑publication FOLFIRINOX art. No defensive aggregator (Unified Patents, RPX, etc.) appears in the chain on the '442 patent. The Google Patents family record shows litigation links for the family (Unified Patents’ Darts‑IP/portal links) pointing at the New Jersey NDA case, not at any PTAB trial. Two caveats on the absence signal: (1) the '442 patent’s 2033 expiry gives generics every incentive to keep attacking later; and (2) PTAB petition volume has collapsed since the 2025 USPTO policy shift (petition filing rate down roughly 75% and institution rates down sharply), so the absence of filings is now a weaker indicator of patent strength than it was in the 2015–2024 era.

Recommended next steps

• No PTAB activity exists on US 9,492,442. State that plainly in any defensive strategy memo; the absence is not a validity finding. There is no FWD to link and no disposition to quote — I could not locate one, and I will not invent one.
• If you are a defendant facing a '442 assertion: your invalidity case is a district‑court case, not an estoppel‑limited PTAB case. Check your § 315(b) clock before considering any IPR — if you were served more than one year ago on a complaint pleading the '442, you are time‑barred (35 U.S.C. § 315(b)) absent a joinder or exception theory. If you were recently served, the window is open and unencumbered by any prior petitioner's estoppel.
• Monitor the family, not the '442: the live administrative action is IPR2025‑00505 (claims 1–15 of US 11,344,552; instituted 2025‑08‑14; § 316(a)(11) FWD deadline ≈ 2026‑08‑14; oral hearing was calendared for 2026‑05‑19). A cancelation of the '552 claims would remove the first‑line‑use patent but would not touch the '442 patent — a favorable outcome there does not clear your '442 risk. Verify the FWD at the PTAB E2E/PTACTS docket for IPR2025‑00505 and via CourtListener for any later Federal Circuit appeal, which I could not confirm.
• Watch the Hatch‑Waxman case: D.N.J. 1:24‑cv‑04991 (consolidated with 1:24‑cv‑08723 and 1:25‑cv‑13647) is where '442 validity will first be adjudicated. Track the invalidity contentions and any Intervet/§ 112 or written‑description challenges to the dosage/UGT1A1*28 limitations, since those are the most likely pressure points on this claim set.
• Refresh the ODP check before relying on this memo: if an IPR/PGR against the '442 is filed and indexed after today's ingest, this analysis changes materially.

Caveats. I did not find, and therefore cannot report, an institution decision, FWD, panel, settlement, or appeal specific to US 9,492,442 — none is on file. Details above for IPR2025‑00505/IPR2025‑01531 concern US 11,344,552, a different patent, and are provided only as family/pattern context; the FWD outcome in IPR2025‑00505 was not verifiable in my sources and is not asserted here.

I'll work from the authoritative patent text first, then try to pull reel/frame and correspondent details from the assignment records and related sources.

Assignment & Ownership Analysis — US 9,492,442 B2

Patent: US 9,492,442 B2 — "Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan"
App. No.: 14/851,111 · Filed: 2015-09-11 · Granted: 2016-11-15 · Priority: 2012-06-13 (PCT/US2013/045495 → 61/659,211; 61/784,382)
Current assignee of record: Ipsen Biopharm Ltd. (Wrexham, GB)
Anticipated expiration: 2033-06-12

Sourcing note (read first). I was able to retrieve the USPTO-derived legal-events record for this patent (as rendered on the Google Patents page, which mirrors the Assignment Center docket). That record exposes recording dates, conveyance types, assignor names and assignee names — but it does not expose reel/frame numbers or the correspondent-of-record attorney. I could not pull the raw Assignment Center abstract of title or its correspondent field with the tooling available in this session, and I will not guess reel/frame numbers or attorney names. Those two fields are reported below as [not retrieved] rather than invented. Everything else is grounded in the recorded events. Verify at: https://assignmentcenter.uspto.gov/ (search by patent number 9492442).

Inventors

Pattern notes:

• All seven inventors assigned (or confirmed assignment of) their rights to Merrimack Pharmaceuticals, Inc. — a single-employer inventor group, no university or third-party co-owner, no government-interest statement.
• Unusual: Kim's assignment was recorded separately and ~5 months later (2016-05-03) than the other six (2015-11-23). A split, out-of-band confirmatory assignment of one inventor is a title-cleanliness tell — commonly filed when one inventor's original employment/confidentiality paperwork is missing or defective and the company needs an unbroken chain before licensing or enforcement.
• Departures: I could not verify individual inventor departure dates from assignment records (assignment records do not carry employment data). What is documented is a company-wide wind-down: Merrimack announced an ~80% workforce reduction in Jan 2017 (≈400 → ≈80), and by May 2019 had dismissed all full-time employees. So all inventors eventually left — but not within 12 months of the 2015-09-11 filing, so this is not a "departure-precedes-fire-sale" signal.

Original assignee

Merrimack Pharmaceuticals, Inc. (Cambridge, MA) — named on the issued patent.

• Product: Yes. Merrimack commercialized the claimed therapy as ONIVYDE® (irinotecan liposome injection), FDA-approved October 2015 in combination with 5-FU/leucovorin for post-gemcitabine metastatic pancreatic adenocarcinoma. This is a product-shipping, claim-embodying original assignee — the opposite of an NPE profile at the origin of the chain.
• Primary line of business: Clinical-stage oncology drug developer (systems-biology/"network biology" platform; liposomal and antibody therapeutics). Publicly traded (NASDAQ: MACK).
• Status: Dissolved. Distressed divestiture of ONIVYDE and generic DOXIL to Ipsen closed April 2017 (up to $1.025B: $575M upfront + $450M milestones); remaining pipeline sold off piecemeal (anti-HER3 program to Elevation Oncology/14ner, July 2019); all employees dismissed by May 2019; Plan of Dissolution approved by stockholders May 2024 after receipt of the $225M Ipsen milestone (FDA first-line mPDAC approval, Feb 2024), with a liquidating trust established.

Assignment timeline

All six events below are recorded USPTO assignments as surfaced in the patent's legal-events record. Reel/frame and correspondent are not exposed in the source I retrieved and are shown as [not retrieved]. Execution dates are likewise not exposed for these entries (which is common for the Google Patents rendering); only the USPTO recording date is available. Where the true execution date matters, I say so.

2015-11-23 (recording date; execution date not exposed) — Reel/Frame [not retrieved]

• Conveyance: Assignment of assignors' interest
• Assignor: Niyikiza, Clet; Moyo, Victor; Bayever, Eliel; Fitzgerald, Jonathan Basil; Dhindsa, Navreet; Laivins, Peter
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: [not retrieved]
• Context: Confirmatory inventor → employer assignment, filed ~2 months after the 2015-09-11 application filing.

2015-12-28 — Reel/Frame [not retrieved]

• Conveyance: Security Interest (patent collateral)
• Assignor: Merrimack Pharmaceuticals, Inc.
• Assignee: U.S. Bank National Association, as Collateral Agent
• Correspondent: [not retrieved]
• Context: Securitization/collateralization — Merrimack pledged its IP as security for the senior secured notes. This is a lien, not an ownership transfer.

2016-05-03 — Reel/Frame [not retrieved]

• Conveyance: Assignment of assignor's interest
• Assignor: Kim, Jaeyeon
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: [not retrieved]
• Context: Late-filed confirmatory assignment from the seventh inventor — a title-cure step, ~5 months after the other six.

2017-04-14 — Reel/Frame [not retrieved]

• Conveyance: Release by Secured Party
• Assignor: U.S. Bank National Association
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: [not retrieved]
• Context: Lien release after Merrimack redeemed its secured notes out of the Ipsen proceeds (public reporting: ~$195.1M of senior secured notes redeemed). This, not a sale, is why the encumbrance disappears — important because it means the patent reached Ipsen unencumbered.

2017-05-01 — Reel/Frame [not retrieved]

• Conveyance: Assignment of assignor's interest
• Assignor: Merrimack Pharmaceuticals, Inc.
• Assignee: Ipsen Biopharm Ltd.
• Correspondent: [not retrieved]
• Context: Corporate asset sale — the ONIVYDE/MM-398 transaction (up to $1.025B; $575M upfront, $450M regulatory milestones). Ipsen is an operating specialty-pharma purchaser, not an IP-holding vehicle. This is the only true change of ownership in the chain.

2017-05-17 — Reel/Frame [not retrieved]

• Conveyance: Change of Address of Assignee
• Assignor: Merrimack Pharmaceuticals, Inc. (nominal)
• Assignee: Ipsen Biopharm Ltd.
• Correspondent: [not retrieved]
• Context: Administrative address update only — no change in ownership.

Correspondent recurrence — cannot be assessed. The signal the brief asks me to weight most heavily (one repeat-player attorney running every recording) is not evaluable here because no correspondent field was retrievable for any of the six entries. I flag this explicitly rather than assert it either way.

Two related leads (not findings, and deliberately not treated as correspondents):

• The prosecution firm of record on a later-issued, same-assignee liposome patent in this technology family (US 12,059,497 B2, Ipsen Biopharm Ltd.) is McNeill Baur PLLC. That is patent-prosecution counsel on a different family (stabilizing camptothecin compositions), not the assignment correspondent for US 9,492,442, and I am not inferring a link.
• The 2024 D.N.J. complaint was signed by Charles Lizza — that is litigation counsel, not a recording correspondent, and must not be conflated with the assignment field.

Timeline diagram

timeline
    title Ownership of US 9492442
    2012 : Priority filing by Merrimack
    2015 : US application filed
         : Six inventor assignments recorded
         : Onivyde FDA approval
         : Security interest to US Bank recorded
    2016 : Kim confirmatory assignment recorded
    2017 : Security interest released
         : Ownership transferred to Ipsen Biopharm Ltd
         : Ipsen address change recorded
    2019 : Merrimack dismisses all staff
    2024 : Ipsen sues generic filers in D NJ
         : Merrimack approves plan of dissolution

NPE / troll-pattern signals

1. Shell-entity transfer — Not present.
The only ownership transfer (recorded 2017-05-01) runs from an operating drug developer (Merrimack) to an operating pharmaceutical manufacturer (Ipsen Biopharm Ltd., part of Euronext-listed Ipsen S.A.). No "IP / Holdings / Ventures / Licensing" suffix appears anywhere in the chain; the assignee is the same legal entity that markets the product. The IP / Patents / Licensing / Holdings name test and the no-products-in-commerce test both fail.

2. Known asserter in the chain — Not present.
Neither Merrimack Pharmaceuticals, Inc. nor Ipsen Biopharm Ltd. matches any entry on the NPE directories cited (Acacia, Marathon, IV, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities), and neither surfaces as a high-frequency plaintiff. Ipsen is a commercial specialty-pharma group and, critically, is the plaintiff asserting as the record owner, which is the classic operating-company posture.

3. Repeat correspondent across the chain — Unclear / not assessable.
No correspondent-of-record data was retrievable for any of the six recording events, so the recurrence signal cannot be scored. I will not manufacture an attorney name to fill the gap. This is the single largest evidentiary hole in this analysis and is a data-access limitation, not a negative finding.

4. Cascading transfers — Not present.
There is exactly one change of ownership over the life of the patent (Merrimack → Ipsen, recorded 2017-05-01). The other five events are: two confirmatory inventor assignments, one security interest, one release of that interest, and one change-of-address. No chained LLCs, no shared-correspondent address cluster, no succession of assignees inside 24 months.

5. Pre-litigation transfer — Not present.
The first (and only) infringement suit, D.N.J. 3:24-cv-04991, was filed 2024-04-15 — roughly seven years after the 2017-05-01 transfer to Ipsen. A seven-year gap is inconsistent with the "buy-then-sue within 6 months to manufacture standing/venue" pattern. Note the converse and more important point: the plaintiff is the long-standing record owner, so there is no standing-arrangement concern.

6. Bankruptcy fire-sale — Not present (with one nuance).
Merrimack never filed Chapter 7 or 11. The 2017-05-01 conveyance was a strategic asset sale under an Asset Purchase and Sale Agreement, approved by stockholders on 2017-03-30, that avoided insolvency — Merrimack's own proxy warned that if the sale failed it "may need to file for bankruptcy." So: a distressed divestiture, yes; a bankruptcy-court sale of the Kodak/Nortel type, no. The final wind-down (Plan of Dissolution, May 2024) was a solvent liquidating distribution, not a bankruptcy.

7. Privateering — Not present.
Ipsen did not acquire the patent to assert it against Merrimack's competitors on Merrimack's behalf. It acquired the product (ONIVYDE), continued selling it, and expanded its own label (first-line mPDAC approval, Feb 2024). Any assertion is in Ipsen's own commercial self-interest as manufacturer — the inverse of the privateering structure (where the operating company stays in the background while the NPE fronts the litigation).

8. Defensive aggregator — Not present.
The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. It terminates at an entity that is actively litigating. No neutralization signal.

Verdict

Operating-company assertion

Ipsen Biopharm Ltd. is the current assignee by virtue of the single ownership transfer of record, recorded 2017-05-01 (Merrimack Pharmaceuticals, Inc. → Ipsen Biopharm Ltd.), and it holds the patent free of the U.S. Bank security interest released 2017-04-14. Ipsen manufactures and sells the claim-embodying product — ONIVYDE (irinotecan liposome injection), FDA-approved October 2015 — and is the named plaintiff in D.N.J. 3:24-cv-04991 (Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc., CSPC Ouyi Pharmaceutical Co., Ltd., CSPC Pharmaceutical Group Limited), an ANDA/generic-competitor action against actual rivals rather than a licensing-only plaintiff. Every NPE-specific signal tested above scored not present; the only actionable gap is the correspondent field, which was not retrievable from the source available to me and should be pulled from the Assignment Center abstract of title if a correspondent-recurrence check is required. On the evidence that is of record, this is a conventional operating-company enforcement chain.

Verification: https://assignmentcenter.uspto.gov/ (search patent number 9492442) · litigation docket: https://www.courtlistener.com/docket/68437697/ipsen-biopharmaceuticals-inc-v-conjupro-biotherapeutics-inc/

Remaining data gap to close: reel/frame numbers and correspondent-of-record for all six recording events. I did not retrieve these and have not supplied substitutes.

I'll research the prior art references cited for US 9,492,442, focusing on USPTO-side citation data.

Let me get the specific citation lists from Justia and Google Patents for this patent.

Let me try to access the Justia and FreePatentsOnline pages directly for the specific patent.

Sourcing note (read first)

I was unable to retrieve the USPTO "References Cited" (Section 56) block of US 9,492,442 B2 itself from the sources I could reach — the Google Patents full-text I was given for this patent is truncated before any citation list, and the Justia/FPO pages I could reach returned only the forward citation lists of sibling patents (i.e., later Bayever-family members), not the '442's own backward citations. Treat the list below as family-level citation data, not a verified reproduction of the '442 patent's own front page. Concretely, the references below come from the European search report for the same family/priority chain (EP 2861210 B1 — priority 2012‑06‑13, same inventors/specification), which shares the '442's disclosure, plus Google Patents citation aggregation. The US examiner's citation list for the '442 can and often does differ. Verify the exact (56) list in USPTO Patent Center / the granted-PDF front page before relying on any item.

Also, per the earlier section, the operative claim set of the '442 is itself unverified (aggregator-sourced, with an unresolved UGT1A1/3‑week inconsistency). The claim references below therefore point to claim families, not confirmed claim numbers.

A. Patent-document citations (family-level)

(Directional caution: the many Bayever-family members that surface — US 9,339,497; 9,364,473; 9,452,162; 9,717,724; 10,980,795; 11,369,597; and pre-grant pubs US 2015/0182521, 2015/0328156, 2015/0374682, 2016/0074382, etc. — are forward citations / continuations, not prior art. Do not use them as §102 references against the '442.)

B. Non-patent-literature citations (family EP search report)

C. §102 anticipation analysis (mapped to the claim families from my earlier section)

Claim family 1 — method of treating exocrine pancreatic cancer with liposomal irinotecan + leucovorin + 5‑FU (liposome defined as PC/cholesterol/PEG‑PE, ~80–140 nm):

• No single recovered reference discloses the whole combination with liposomal irinotecan at the recited dose/cycle. Anticipation requires a single reference disclosing every element (MPEP 2131).
• P1 (US 8,147,867) can anticipate only the compositional element; it lacks the treatment/dosing elements.
• N1 (Ko 2011) discloses liposomal irinotecan in pancreatic cancer but monotherapy, no 5‑FU/LV → cannot anticipate the combination claims.
• N4–N8 (FOLFIRI art) disclose the triad but with free irinotecan → under §102, a reference disclosing "irinotecan" generically does not also disclose the "liposomal" limitation; these are §103 references, not §102 anticipators, for claims that recite liposomal irinotecan.

Claim family 4/8/10 — gemcitabine‑pretreated patients; liposomal irinotecan 60–80 mg/m²; leucovorin 200 mg/m² (l‑form)/400 mg/m² (racemic); 5‑FU 2,400 mg/m²; sequential dosing day 1 of a 2‑week cycle:

• N1 (Ko 2011) anticipates the "gemcitabine‑refractory pancreatic cancer treated with liposomal irinotecan" population/active element, and US 8,147,867 supplies the composition; but neither supplies the specific 60–80 mg/m² + 2,400 mg/m² 5‑FU + 200/400 mg/m² LV + 2‑week cycle combination. No single reference anticipates the full claim; the combination is an obviousness question (§103), typically framed as liposomal‑irinotecan art (N1/N2/P1) in view of FOLFIRI art (N4–N8) with a dosing‑optimization rationale.
• N9 (Hoskins 2007) would anticipate/obviously render any claim that recites UGT1A1*28‑stratified dosing — this is precisely the limitation whose presence in the granted claims I could not confirm.

"Increasing tumor vascularity" aspect: N10 (Waterhouse 2011) is the direct §102 hit, since it expressly attributes a dual chemo/angiogenic (vascular) mechanism to lipid‑formulated irinotecan.

Timing filter that matters: Because the '442 carries a 2012‑06‑13 prior‑art date, references published after that date (Neuzillet Sept 2012, Infante Oct 2012, the cited Camptosar July‑2012 label, the Jan‑2013 NAPOLI‑1 posting) are not prior art unless an earlier effective date applies — so on the face of it the real §102/§103 universe is: Ko 2011, Chen 2008, Taïeb 2007, Yoo 2009, Gebbia 2010, Hoskins 2007, Waterhouse 2011, Tsai 2011, Fusilev 2008, US 8,147,867, and the pre‑2012 WO documents. (If the 2012‑06‑13 priority were ever held invalid, as was argued for the sibling '552 patent's 2015 filing date, the post‑2012 references would move into the art — a material contingency.)

D. Bottom line / what I could not establish

1. No single reference of record anticipates the full combination claims as I can reconstruct them; the references divide into (a) liposomal‑irinotecan composition/clinical art (P1, N1, N2, N3) and (b) FOLFIRI free‑irinotecan pancreatic art (N4–N8). The strongest §102 reference is Ko 2011 (N1) against monotherapy/gemcitabine‑refractory claims; the strongest §103 attack is N1/N2/P1 + N4–N8.
2. I could not verify the '442 patent's own (56) "References Cited" block, the content/date of WO 2012/146610 A1 and WO 2013/138371 A1, or the granted claim numbers/set — so the anticipatory-claim mapping is necessarily at the claim‑family level. The single most inspection‑worthy item is the USPTO Patent Center front page / PTActs for 9,492,442.
3. Per the strict operating rule, all identifiers above are reproduced literally (including the source's OCR artifact "S.about.Fluorouracil" in the NCT01494506 entry) and have not been auto‑corrected.

I'll ground this analysis in the actual prior-art record. Let me pull the key references.

Let me verify the actual issued claims and the prior-art references used in the related IPR proceedings.

Obviousness analysis — U.S. 9,492,442 B2 under 35 U.S.C. § 103

Note on the "Prior Art section." The Google Patents text supplied in this task does not contain a prior-art citation table — its only prior-art signals are (i) the five "Prior art keywords" (irinotecan, dose, leucovorin, patient, administered), (ii) the U.S. Pat. No. 8,147,867 cross-reference in §II of the description ("see U.S. Pat. No. 8,147,867"), and (iii) the "Bayever" reference (Ex. 1006) relied on in the co-pending IPR against the sibling patent U.S. 11,344,552. I have therefore built the analysis on (a) those in-page references, (b) the references actually relied on in that IPR record (Conroy; Bayever; and "Mahaseth," which I could not verify and flag as unconfirmed below), and (c) the primary literature that the '442 specification itself treats as the state of the art. Where I could not verify a reference's content or date, I say so.

Resolution of the open item flagged in the earlier summary. The claim text I previously could not verify is now confirmed to a single consistent claim set across two independent fetches of the same aggregator (drugpatentwatch "Patent Claims" and "Non-Orange Book" tabs for 9,492,442, last updated 2026-07-25/2026-08-15). Critically, the issued claims as displayed contain no UGT1A1*28 limitation and no 3-week/120 mg/m² limitation. Those limitations appear only in the specification and in sibling patents of the same family. The earlier "inconsistency to resolve" is therefore resolved in favor of explanation (a)/(b): the aggregator is displaying the '442 claim set, which is the q2w 5-FU/LV combination set, matching the Orange Book use code ("…IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN"). This materially changes the §103 analysis, because the genotype/120 mg/m² subject matter is not in the claims to be challenged.

A. The legal frame

• Effective filing date: 2012-06-13 (US 61/659,211), with 2013-03-14 (US 61/784,382) as a second priority. The application is post-AIA (filed 2015; parent 2014), so §102(a)(1)/(a)(2) with §102(b) exceptions governs. Prior art must pre-date 2012-06-13 (or, for claims not supported by the first provisional, 2013-03-14).
• Standard: KSR Int'l v. Teleflex, 550 U.S. 398 (2007) — a combination is obvious if a POSA would have had a reason to combine with a reasonable expectation of success, and "obvious to try" with predictable results suffices. Numerical dose/volume limitations are ordinarily "result-effective variables" subject to routine optimization (In re Aller; In re Boesch) absent a showing of criticality.
• Claims 1–9 are open-ended ("comprising"); claim 10 is closed ("consisting of"), so for claim 10 any third active ingredient defeats infringement but also narrows the obviousness case.

B. What the claims require (verified text)

Two observations that drive everything below: (1) every claim is a method of using a known drug combination against a known disease; and (2) the only arguably non-conventional elements are the liposomal encapsulation (a formulation feature) and the specific doses/volumes/schedule.

C. The prior-art record

D. Ground 1 — Primary combination: '867 + Conroy (and, alternatively, '867 + Yoo)

Proposed rejection. Claims 1–3, 5–7, 9, and (with Yoo) 4, 8, 10.

1. '867 supplies every formulation element. The liposomal irinotecan composition of claim 1 (PC/cholesterol/PEG-PE; 80–140 nm) and of claim 3 (unilamellar vesicles encapsulating irinotecan sucrose octasulfate) is the MM-398 composition whose enabling disclosure the '442 specification itself concedes resides in '867 ("also known as PEP02, see U.S. Pat. No. 8,147,867"). '867 discloses the SOS trapping-agent chemistry, the uncharged-lipid/neutral-phospholipid membrane, long-circulating (≥24 h half-release) liposomes, and mammalian xenograft superiority over free irinotecan at equal dose. The 80–140 nm diameter and ≈1 PEG per 200 phospholipids are either disclosed or, at minimum, routine liposome-engineering parameters (extrusion sizing; 5 mol% PEG-lipid molar ratio is a standard "stealth" formulation range).

2. Conroy supplies every dosing/scheduling element of claims 5–7 and the 2-week cycle of claim 6. Conroy expressly administers 5-FU 2,400 mg/m² over 46 hours, leucovorin 400 mg/m², irinotecan, on a 14-day cycle, to metastatic pancreatic cancer patients — i.e., the same drug classes, the same 5-FU dose, the same cycle length, and the same disease as claims 1 and 5–6. Yoo supplies the same for a 5-FU/LV/irinotecan backbone in gemcitabine-refractory disease, with LV 400 mg/m² (and the GISCAD registry/levoleucovorin labeling supply the 200 mg/m² l-form half-dose equivalence).

3. The only delta is the substitution of liposomal irinotecan for free irinotecan — and the art supplies the motivation and the expectation of success.

• Motivation: '867 teaches that the liposomal form is 4–10× more active than free irinotecan at the same dose and schedule, with the same or better toxicity — exactly the improvement a POSA pursuing a regimen whose principal limitation is irinotecan-related toxicity and modest efficacy (Conroy reports 5.4% febrile neutropenia and QoL degradation) would seek.
• Same active moiety: the '442 specification itself concedes the mechanism: "once irinotecan leaves the liposomes, it is catabolized by the same metabolic pathways as conventional (free) irinotecan." A POSA would therefore expect the same pharmacology and no loss of efficacy.
• Predictable result: substituting a long-circulating, EPR-targeted depot form of the same drug into a known 5-FU/LV backbone is a "predictable variation" in the KSR sense, not the discovery of a new use.

Conclusion on Ground 1: on this record, claims 1–3, 5–7 and 9 are, at a minimum, prima facie obvious, and a challenger would have a strong KSR case.

E. Ground 2 — Adding Yoo (or GISCAD) for the gemcitabine-refractory limitation (claims 4, 8, 10)

Claims 4, 8 and 10 require prior gemcitabine therapy/progression. Yoo 2009 is directly on point: it is a randomized phase II of a 5-FU/LV/irinotecan regimen specifically in gemcitabine-refractory advanced pancreatic cancer, every 2 weeks, reporting manageable toxicity and modest activity, and its own introduction notes that "several investigators have … conducted pilot or phase II trials with combinations such as FOLFIRI … FOLFOX … IROX." The '442 specification independently acknowledges that gemcitabine is the first-line standard and that "single agent gemcitabine was also approved as second line treatment for patients previously treated with but no longer responsive to 5-fluorouracil."

Motivation: once first-line gemcitabine fails, a POSA had both a clinical need (no validated second-line standard) and an explicit literature pointer (Yoo; the GISCAD trial's stated rationale: "Basing on the high expression of Topoisomerase I and Thymidilate Synthase in pancreatic cancer, Irinotecan and 5-Fluorouracil … have shown to be active"). This is a textbook articulated rationale — same disease, same clinical stage, same drug classes.

F. Ground 3 — The numerical limitations of claims 5, 7, 9, 10, 11

The concentration on these limitations is important: claim 10's closed "consisting of" transition and its 60–80 mg/m² range are the most plausible non-obviousness footholds, but both are, on their face, optimization of a known variable.

G. Why a POSA would have combined these references (KSR articulation)

A challenger should plead each KSR rationale expressly:

1. Combining prior-art elements according to known methods to yield predictable results — substituting the liposomal form of a drug already in the regimen (Conroy/Yoo) for the free form ('867), keeping the 5-FU/LV backbone and q2w cycle intact.
2. Simple substitution of one known element for another to obtain its known advantages — '867's own claim 3 quantifies the advantage (≥4–10× activity vs free irinotecan at equal dose/schedule), and its long half-release addresses the drug's known shortcomings (toxicity; schedule dependence).
3. Use of a known technique to improve a similar device in the same way — PEGylated long-circulating liposomes (EPR/"stealth") applied to a known chemotherapy regimen.
4. Obvious to try — the number of identified, predictable solutions was small (liposomal irinotecan was one of the few clinically advanced reformulations of an agent already validated in this disease), and the art supplied a "reasonable expectation of success" because the active moiety is unchanged.
5. Design incentives / market demand — pancreatic cancer is "dismal" with "a dearth of effective therapies" ('442 Background, and Conroy's own framing).

POSA definition (adopt the IPR record's formulation, which the parties there disputed only marginally): an M.D./Ph.D.-level medical oncologist in GI cancers, or a pharmaceutical scientist in drug delivery with 1–2 years' post-doctoral experience, working as part of a multidisciplinary team.

H. The non-obviousness defenses the Patent Owner will (and did) press

These are the counter-arguments a §103 challenge must answer, and they are non-trivial:

1. Unexpected results / therapeutic synergy. The specification itself claims "therapeutic synergy" (defined per Corbett et al., Cancer Treatment Reports 1982;66:1187), and NAPOLI-1 — though post-priority and unusable as art — is the kind of evidence a Patent Owner uses to show results not predictable from any reference. In the co-pending IPR on the sibling '552 patent, Ipsen successfully argued unexpected efficacy and safety over Conroy + Bayever after the Examiner had repeatedly rejected the claims on those references.
2. No reasonable expectation of success in this field. The record in the related IPR states pancreatic cancer had the "highest Phase III failure rate of all cancers at 87%" and Ipsen argued that preclinical/early-stage data "does not predict clinical trial success." A challenger relying on mouse xenograft data from '867 to forecast clinical success must rebut this.
3. Teaching away / alternative routes. Conroy's FOLFIRINOX toxicity and the availability of non-irinotecan second-line options (FOLFOX/OFF; the CONKO-003 data) could be argued to steer a POSA away from an irinotecan second-line therapy in gemcitabine-failure patients — though Yoo, IROX and the GISCAD trial undercut that argument badly.
4. Criticality of the dose range. For claim 10, Patent Owner can argue that 60–80 mg/m² is a critical range (not merely a result-effective variable), and point to the '552 prosecution where the Examiner's "result-effective variable" theory was ultimately overcome.
5. Hindsight. The Ipsen brief in the '552 IPR makes precisely this point — that the petitioner "began with FOLFIRINOX … working backward from the claimed invention," which is the classic hindsight objection to a Conroy-anchored ground. A challenger must build the ground from the art's own problem statement, not from the claims.

I. What a §103 challenge to the '442 could not properly rely on

• The "Bayever" reference. The reference cited as Ex. 1006 throughout the '552 IPR record is the '442's own disclosure (Arm C: MM-398 80 mg/m² q2w + 5-FU/LV; second-line gemcitabine-progressed patients; MM-398 → LV → 5-FU ordering). It is prior art to the later '552 patent (effective filing 2015-08-21) via §102(a)(2) — but it is the same inventive entity/family as the '442 and cannot be prior art against the '442 itself (it post-dates the '442 priority date and is not "by another"). Any search result or brief that treats "Bayever" as prior art to the '442 is conflating the patents. This is the single most likely error a secondary source will make about this family.
• NAPOLI-1 (2015/2016), NCCN 2016 guidelines, Ko 2016, the '360/'497/'691/'914 patents, and U.S. 11,344,552. All post-date the 2012-06-13 priority date. Their presence in the ecosystem is evidence of commercial success and copying-type indicia, not §102 art.
• "Mahaseth." Relied on in the '552 IPR for LV-then-5-FU ordering, but its publication appears to post-date the '442 priority; verify before use.
• The '442 specification's own UGT1A1*28 discussion. Not in the issued claims; the Camptosar label (§C) is real prior art but is irrelevant to the claims as issued. If (as I cannot fully rule out) a reexamination certificate or a corrected claim set reintroduces a UGT1A1*28 limitation, then the May 2010 Camptosar labeling change would itself be a powerful §103 reference for that limitation, because the label states that homozygotes "should be treated at a lower dose" and that the "precise dose reduction … is not known" — i.e., it expressly directs routine optimization. That is a fact worth preserving for any future reexamination.

J. Bottom line, and confidence

Bottom line. On the verified claim text, a well-pleaded §103 case exists for every claim of the '442:

• Primary ground: U.S. 8,147,867 + Conroy 2011 (NEJM) → claims 1–3, 5–7, 9.
• Secondary ground: + Yoo 2009 (Br J Cancer) (and/or GISCAD NCT01543412) → claims 4, 8, 10.
• Optimization ground: + Conroy's 2,400 mg/m²/46-h 5-FU, the levoleucovorin half-dose convention, '867's storage data, and the irinotecan combination-sequence labeling → claims 5–7, 9, 10, 11.
• The UGT1A1*28 / q3w-120 mg/m² subject matter emphasized in the specification is not claimed and should play no role in a §103 attack on this patent.

The hard part of the case is not the combination — the art maps almost element-for-element — it is defeating the unexpected-results and no-reasonable-expectation-of-success defenses, which succeeded in prosecution of the sibling '552 patent.

Confidence:

• High: the prior-art dates and content of '867 (issued 2012-04-03; drugpatentwatch claim text; cross-referenced in the '442 specification) and Conroy (NEJM 2011; 5-FU 2,400 mg/m² over 46 h; LV 400 mg/m²; q2w; metastatic pancreatic cancer); Yoo 2009 (gemcitabine-refractory, mFOLFIRI.3, q2w); and that "Bayever" is the '442 family document, not independent art against the '442.
• Moderate: the claim-1 preamble (the dosing/patient limitation preceding the recovered text is still not captured — claims 6 and 8 refer back to "the diluted irinotecan injection formulation," so claim 1 almost certainly recites it, but I have not seen the full sentence); and the Drummond 2006 citation details.
• Not established: whether '867 discloses the 80–140 nm figure and the 1:200 PEG ratio numerically (if not, those become routine-optimization arguments, which is a weaker but still viable position); the first-posted date of NCT01543412; and the citation identity of "Mahaseth." All three should be verified against the primary documents (USPTO Patent Center "Claims" tab for the '442; the '867 patent specification; clinicaltrials.gov; and the '552 IPR exhibit list) before any of this is relied on in a filing.